SCHEMBL7567719

SCHEMBL7567719

COc1cc(NC(=O)OCc2cc(N)cc(Nc3c4ccccc4nc4ccccc34)c2)cc(OC)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 9/20 0.73
TOP2B Q02880 8/20 0.73
POLB P06746 7/20 0.46
RAD52 P43351 3/20 0.46
KMT2A Q03164 3/20 0.46
KDM1A O60341 2/20 0.46
GFER P55789 1/20 0.46
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 2/20 0.46
GLA P06280 1/20 0.45
TDP1 Q9NUW8 2/20 0.43
PPARG P37231 1/20 0.43
NR2E3 Q9Y5X4 1/20 0.43
NCOR2 Q9Y618 1/20 0.43
TACR3 P29371 1/20 0.43
LMNA P02545 3/20 0.42
MAPT P10636 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7564523 0.93 TOP2A (0.71) TOP2ATOP2BPOLBRAD52KMT2A
SCHEMBL7563689 0.89 TOP2A (0.77) TOP2ATOP2BPOLBRAD52KMT2A
SCHEMBL3981533 0.89 TOP2A (0.80) TOP2ATOP2BPOLBRAD52KMT2A
SCHEMBL7562964 0.89 TOP2A (0.71) TOP2ATOP2BPOLBRAD52KMT2A
SCHEMBL7563941 0.89 TOP2A (0.62) TOP2ATOP2BPOLBRAD52KMT2A
SCHEMBL3985960 0.88 TOP2A (0.59) TOP2ATOP2BPOLBRAD52KMT2A
SCHEMBL6546437 0.86 TOP2A (0.76) TOP2ATOP2BPOLBRAD52KMT2A
SCHEMBL7568574 0.86 TOP2A (0.73) TOP2ATOP2BPOLBRAD52KMT2A
SCHEMBL7567330 0.86 TOP2A (0.73) TOP2ATOP2BPOLBRAD52KMT2A
SCHEMBL7567582 0.86 TOP2A (0.73) TOP2ATOP2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020111491-A1 9-aminoacridine derivatives and process for the preparation thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2002-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111491-A1 9-aminoacridine derivatives and process for the preparation thereof ALKBH1, ADCY9, CCR9 TOP2A 1105/4885TOP2B 841/4885POLB 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.